N/A
N=74
Lipids, Inflammation, and CV Risk in RA
Rheumatoid Arthritis · Cardiovascular Disease
Bottom Line
View on ClinicalTrials.gov: NCT02714881 ↗Enrolled (actual)
74
Serious AEs
2.7%
Results posted
Jan 2026
Primary outcome: Primary: Coronary Flow Reserve — 2.65 ratio
Study Design & Population
- Study type
- Observational
- Phase
- N/A
- Interventions
- Certolizumab (Drug)
- Age
- Adult, Older Adult · 35+ yrs
- Sex
- All
- Sponsor
- Brigham and Women's Hospital
- Primary completion
- Dec 2020
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY Coronary Flow Reserve |
2.65 | — |
Summary
The objective of this study was to examine the relationship between inflammation, lipids, and cardiovascular risk in rheumatoid arthritis. The central hypothesis is that reducing inflammation will reduce cardiovascular risk as measured by coronary flow reserve. Additionally, we hypothesized that lipid levels may have a weaker correlation with CV risk compared to the general population.
Eligibility Criteria
Inclusion Criteria
- RA diagnosed by a rheumatologist
- Fulfills the 2010 American College of Rheumatology (ACR)/European League Against Rheumatism (EULAR) Criteria for RA
- Age>35
- Active RA as defined by treating rheumatologist
- Biologic DMARD naive
Exclusion Criteria
- Patients on statin or PCSK9 inhibitor therapy
- Corticosteroid therapy >10mg prednisone or its equivalent as a maintenance treatment
- Pregnancy
- Unstable angina (chest pain) or shortness of breath
- Severe valvular heart disease
- Myocarditis
- Pericarditis
- Asthma with active wheezing
- History of lymphoproliferative disease or melanoma (stage two or higher), active malignancy, or cancer treatment in the last 5 years
- Active infectious disease (HIV, Tuberculosis, or Hepatitis B/C)
Data sourced from ClinicalTrials.gov (NCT02714881). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.